Punit Dhillon News Today

Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026San Diego, California--(News...

Skye Bioscience, Inc. , a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid...

Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skyes diff...

San Diego, California--(Newsfile Corp. - January 29, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage

Breaking Biotech Funding News - Skye Bioscience (OTCQB: SKYE) Announces $50.25 Million Private Placement Equity Financing

Skye Bioscience, Inc. , a clinical stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid...

Skye Bioscience, Inc. , a pharmaceutical company developing drugs targeting the endocannabinoid system, has received clearance of its Investigational New Drug application with the U.S. Food and Drug...

Skye Bioscience has announced its plans to develop nimacimab, the company’s monoclonal antibody recently acquired from Bird Rock Bio, for weight loss and the treatment of obesity.

Skye Bioscience, Inc. , a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes, with...

Acquisition of Bird Rock Bio builds Skyes position as a leading endocannabinoid system-focused pharmaceutical company •New capital funds anticipated Phase 2a glaucoma...